Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Abstract

Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics; FELIX ClinicalTrials.gov number, NCT04404660.).